Atogepantdosage

QULIPTA is taken orally with or without food. For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily. For chronic migraine, the recommended dosage is 60 mg taken once daily. Severe Renal Impairment or End-Stage Renal Disease: Episodic migraine: 10 mg once daily.

Chronic migraine: Not recommended.

2.1 Recommended

Dosage QULIPTA is taken orally with or without food. Episodic Migraine The recommended dosage of QULIPTA for episodic migraine is 10 mg, 30 mg, or 60 mg taken once daily. Chronic Migraine The recommended dosage of QULIPTA for chronic migraine is 60 mg taken once daily.

2.2 Dosage Modification s

Dosage modifications and usage recommendations for episodic and chronic migraine with concomitant use of specific drugs and for patients with renal impairment are provided in Table 1.

Table 1: Dos age Modifications for Drug Interactions and for Specific Populations Dosage Modifications Recommended Once Daily Dosage for Episodic Migraine Usage and Recommended Once Daily Dosage for Chronic Migraine Concomitant Drug Strong CYP3A4 Inhibitors 10 mg 10 mg Strong CYP3A4 Inducers 60 mg a Not recommended Moderate CYP3A4 Inducers 60 mg Not recommended Weak CYP3A4 Inducers 30 mg or 60 mg 60 mg a OATP Inhibitors 10 mg or 30 mg 30 mg Renal Impairment Severe Renal Impairment and End-Stage Renal Disease (CLcr <30 mL/min) 10 mg Not recommended a Coadministration decreases atogepant exposure. Monitor for reduced efficacy.